AgomAb Therapeutics NV American Depositary Shares Asset Resilience Ratio
AgomAb Therapeutics NV American Depositary Shares asset resilience ratio. AgomAb Therapeutics NV American Depositary Shares (AGMB) has an Asset Resilience Ratio of 19.58% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does AgomAb Therapeutics NV American Deposita carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of AgomAb Therapeutics NV American Depositary Shares (2021–2025)
Asset resilience ratio of AgomAb Therapeutics NV American Depositary Shares from 2021 to 2025. This chart shows how AgomAb Therapeutics NV American Depositary Shares's Asset Resilience Ratio has changed over time. See AgomAb Therapeutics NV American Deposita financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down AgomAb Therapeutics NV American Depositary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see AGMB current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $30.10 Million | 19.58% |
| Total Liquid Assets | $30.10 Million | 19.58% |
Asset Resilience Insights
- Good Liquidity Position: AgomAb Therapeutics NV American Depositary Shares maintains a healthy 19.58% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
AgomAb Therapeutics NV American Depositary Shares Industry Peers by Asset Resilience Ratio
Compare AgomAb Therapeutics NV American Depositary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
AgomAb Therapeutics NV American Depositary Shares Asset Resilience Ratio by Year (2021–2025)
AgomAb Therapeutics NV American Depositary Shares asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for AgomAb Therapeutics NV American Depositary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 19.58% | $30.10 Million | $153.71 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $206.36 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $171.26 Million | -- |
| 2022-12-31 | 39.61% | $40.00 Million | $101.00 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $84.00 Million | -- |
About AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinica… Read more